ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants......http://www.natap.org/2013/EASL/EASL_85.htm
EASL/2012: PRECLINICAL CHARACTERISTICS OF ACH-3102: A NOVEL HCV NS5A INHIBITOR WITH IMPROVED POTENCY AGAINST GENOTYPE-1A VIRUS AND VARIANTS RESISTANT TO 1ST GENERATION NS5A INHIBITORS.....http://www.natap.org/2012/EASL/EASL_79.htm
EASL/2013: ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity (single-dose) in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants ........http://www.natap.org/2013/EASL/EASL_85.htm
EASL/2013: FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS......http://www.natap.org/2013/EASL/EASL_84.htm
ACH-3102 and Ribavirin in Genotype-1b Hepatitis C Patients: Confirmation of the High Barrier to Viral Breakthrough in Genotype-1b HCV......http://www.natap.org/2014/APASL/APASL_28.htm
